Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program
This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were ana...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2014-09, Vol.32 (27), p.2975-2982 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2982 |
|---|---|
| container_issue | 27 |
| container_start_page | 2975 |
| container_title | Journal of clinical oncology |
| container_volume | 32 |
| creator | Lieu, Christopher H Renfro, Lindsay A de Gramont, Aimery Meyers, Jeffrey P Maughan, Timothy S Seymour, Matthew T Saltz, Leonard Goldberg, Richard M Sargent, Daniel J Eckhardt, S Gail Eng, Cathy |
| description | This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study.
Of total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status.
Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted. |
| doi_str_mv | 10.1200/JCO.2013.54.9329 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4809210</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1634723529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-8601d4e6453b3522ca598c7ad901f0047e6c2d0a60420175dfc7479a75dec48d3</originalsourceid><addsrcrecordid>eNpdUU1P2zAYttAQdIw7p8nH7ZDu9Vec7DApytgYqgSamLSbZRyn9ZTExXaLOPHXcVWGNk623-fj1eMHoTMCc0IBPl22V3MKhM0Fn9eM1gdoRgSVhZRCvEEzkIwWpGK_j9HbGP8AEF4xcYSOqQCgksIMPTYxeuN0cn7Cvsd6afG9SyscN2HrtnrAbsLrDNspxT0y2qRjyiODjR98sCZlmtGTseEz1pMeHqKLuA9-xGllcfOzbb7idnCTM5l4E5weIr4Ofhn0-A4d9vlpT5_PE_Tr2_lNe1Esrr7_aJtFYTiDVFQlkI7bkgt2ywSlRou6MlJ3NZAegEtbGtqBLoHn_5Ci643kstb5Zg2vOnaCvux915vb0XYmxwl6UOvgRh0elNdO_Y9MbqWWfqt4BTUlkA0-7g1Wr2QXzULtZsBYVUsmtyRzPzwvC_5uY2NSo4vGDoOerN9ERUrGJc056kyFPdUEH2Ow_Ys3AbXrWOWO1a5jJbjadZwl7_-N8iL4Wyp7Akrbo0k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634723529</pqid></control><display><type>article</type><title>Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lieu, Christopher H ; Renfro, Lindsay A ; de Gramont, Aimery ; Meyers, Jeffrey P ; Maughan, Timothy S ; Seymour, Matthew T ; Saltz, Leonard ; Goldberg, Richard M ; Sargent, Daniel J ; Eckhardt, S Gail ; Eng, Cathy</creator><creatorcontrib>Lieu, Christopher H ; Renfro, Lindsay A ; de Gramont, Aimery ; Meyers, Jeffrey P ; Maughan, Timothy S ; Seymour, Matthew T ; Saltz, Leonard ; Goldberg, Richard M ; Sargent, Daniel J ; Eckhardt, S Gail ; Eng, Cathy ; Aide et Recherche en Cancérologie Digestive Foundation</creatorcontrib><description>This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study.
Of total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status.
Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2013.54.9329</identifier><identifier>PMID: 25002720</identifier><language>eng</language><publisher>United States: American Society of Clinical Oncology</publisher><subject>Adult ; Age Factors ; Aged ; Clinical Trials as Topic ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Databases, Factual ; Female ; Humans ; Kaplan-Meier Estimate ; Life Sciences ; Male ; Middle Aged ; ORIGINAL REPORTS ; Proportional Hazards Models ; Risk</subject><ispartof>Journal of clinical oncology, 2014-09, Vol.32 (27), p.2975-2982</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2014 by American Society of Clinical Oncology 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-8601d4e6453b3522ca598c7ad901f0047e6c2d0a60420175dfc7479a75dec48d3</citedby><cites>FETCH-LOGICAL-c430t-8601d4e6453b3522ca598c7ad901f0047e6c2d0a60420175dfc7479a75dec48d3</cites><orcidid>0000-0001-7940-9877</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3716,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25002720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-angers.hal.science/hal-03389737$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Lieu, Christopher H</creatorcontrib><creatorcontrib>Renfro, Lindsay A</creatorcontrib><creatorcontrib>de Gramont, Aimery</creatorcontrib><creatorcontrib>Meyers, Jeffrey P</creatorcontrib><creatorcontrib>Maughan, Timothy S</creatorcontrib><creatorcontrib>Seymour, Matthew T</creatorcontrib><creatorcontrib>Saltz, Leonard</creatorcontrib><creatorcontrib>Goldberg, Richard M</creatorcontrib><creatorcontrib>Sargent, Daniel J</creatorcontrib><creatorcontrib>Eckhardt, S Gail</creatorcontrib><creatorcontrib>Eng, Cathy</creatorcontrib><creatorcontrib>Aide et Recherche en Cancérologie Digestive Foundation</creatorcontrib><title>Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study.
Of total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status.
Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Clinical Trials as Topic</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Databases, Factual</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>ORIGINAL REPORTS</subject><subject>Proportional Hazards Models</subject><subject>Risk</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUU1P2zAYttAQdIw7p8nH7ZDu9Vec7DApytgYqgSamLSbZRyn9ZTExXaLOPHXcVWGNk623-fj1eMHoTMCc0IBPl22V3MKhM0Fn9eM1gdoRgSVhZRCvEEzkIwWpGK_j9HbGP8AEF4xcYSOqQCgksIMPTYxeuN0cn7Cvsd6afG9SyscN2HrtnrAbsLrDNspxT0y2qRjyiODjR98sCZlmtGTseEz1pMeHqKLuA9-xGllcfOzbb7idnCTM5l4E5weIr4Ofhn0-A4d9vlpT5_PE_Tr2_lNe1Esrr7_aJtFYTiDVFQlkI7bkgt2ywSlRou6MlJ3NZAegEtbGtqBLoHn_5Ci643kstb5Zg2vOnaCvux915vb0XYmxwl6UOvgRh0elNdO_Y9MbqWWfqt4BTUlkA0-7g1Wr2QXzULtZsBYVUsmtyRzPzwvC_5uY2NSo4vGDoOerN9ERUrGJc056kyFPdUEH2Ow_Ys3AbXrWOWO1a5jJbjadZwl7_-N8iL4Wyp7Akrbo0k</recordid><startdate>20140920</startdate><enddate>20140920</enddate><creator>Lieu, Christopher H</creator><creator>Renfro, Lindsay A</creator><creator>de Gramont, Aimery</creator><creator>Meyers, Jeffrey P</creator><creator>Maughan, Timothy S</creator><creator>Seymour, Matthew T</creator><creator>Saltz, Leonard</creator><creator>Goldberg, Richard M</creator><creator>Sargent, Daniel J</creator><creator>Eckhardt, S Gail</creator><creator>Eng, Cathy</creator><general>American Society of Clinical Oncology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7940-9877</orcidid></search><sort><creationdate>20140920</creationdate><title>Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program</title><author>Lieu, Christopher H ; Renfro, Lindsay A ; de Gramont, Aimery ; Meyers, Jeffrey P ; Maughan, Timothy S ; Seymour, Matthew T ; Saltz, Leonard ; Goldberg, Richard M ; Sargent, Daniel J ; Eckhardt, S Gail ; Eng, Cathy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-8601d4e6453b3522ca598c7ad901f0047e6c2d0a60420175dfc7479a75dec48d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Clinical Trials as Topic</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Databases, Factual</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>ORIGINAL REPORTS</topic><topic>Proportional Hazards Models</topic><topic>Risk</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lieu, Christopher H</creatorcontrib><creatorcontrib>Renfro, Lindsay A</creatorcontrib><creatorcontrib>de Gramont, Aimery</creatorcontrib><creatorcontrib>Meyers, Jeffrey P</creatorcontrib><creatorcontrib>Maughan, Timothy S</creatorcontrib><creatorcontrib>Seymour, Matthew T</creatorcontrib><creatorcontrib>Saltz, Leonard</creatorcontrib><creatorcontrib>Goldberg, Richard M</creatorcontrib><creatorcontrib>Sargent, Daniel J</creatorcontrib><creatorcontrib>Eckhardt, S Gail</creatorcontrib><creatorcontrib>Eng, Cathy</creatorcontrib><creatorcontrib>Aide et Recherche en Cancérologie Digestive Foundation</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lieu, Christopher H</au><au>Renfro, Lindsay A</au><au>de Gramont, Aimery</au><au>Meyers, Jeffrey P</au><au>Maughan, Timothy S</au><au>Seymour, Matthew T</au><au>Saltz, Leonard</au><au>Goldberg, Richard M</au><au>Sargent, Daniel J</au><au>Eckhardt, S Gail</au><au>Eng, Cathy</au><aucorp>Aide et Recherche en Cancérologie Digestive Foundation</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2014-09-20</date><risdate>2014</risdate><volume>32</volume><issue>27</issue><spage>2975</spage><epage>2982</epage><pages>2975-2982</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC).
A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study.
Of total patients, 3,051 (15%) were age < or =50 years. Age was prognostic for both OS (P < .001)and PFS (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status.
Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.</abstract><cop>United States</cop><pub>American Society of Clinical Oncology</pub><pmid>25002720</pmid><doi>10.1200/JCO.2013.54.9329</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7940-9877</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2014-09, Vol.32 (27), p.2975-2982 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4809210 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Age Factors Aged Clinical Trials as Topic Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Databases, Factual Female Humans Kaplan-Meier Estimate Life Sciences Male Middle Aged ORIGINAL REPORTS Proportional Hazards Models Risk |
| title | Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A27%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20age%20with%20survival%20in%20patients%20with%20metastatic%20colorectal%20cancer:%20analysis%20from%20the%20ARCAD%20Clinical%20Trials%20Program&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Lieu,%20Christopher%20H&rft.aucorp=Aide%20et%20Recherche%20en%20Canc%C3%A9rologie%20Digestive%20Foundation&rft.date=2014-09-20&rft.volume=32&rft.issue=27&rft.spage=2975&rft.epage=2982&rft.pages=2975-2982&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2013.54.9329&rft_dat=%3Cproquest_pubme%3E1634723529%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1634723529&rft_id=info:pmid/25002720&rfr_iscdi=true |